Abstract:Aim: To formulate and assess the anticancer effect of the poly(lactic-co-glycolic acid) (PLGA) copolymer with the thioether groups (diethyl sulfide [Des]) and disulfide bond (cystamine containing disulfide [Cys]), which encapsulated the anticancer drug paclitaxel (PTX) and triggered PTX release in cancer cell H2O2-rich or glutathione-rich surroundings. Methods: PLGA-b-P (Des@Cys) and PLGA-b-P nanoparticles loaded with PTX were prepared and characterized in vitro. The delivery ability of the PLGA-b-P nanoparticles and PLGA-b-P-PTX nanoparticles was assessed on a CT26 (mouse colon cancer cell line) and mouse lung cancer LLC model. Results: The nanoparticles were successfully prepared. Compared with free PTX, the formulated PLGA-b-P nanoparticles loaded with PTX exhibited greater accumulation at the tumor site in the mouse model. Conclusion: PLGA-b-P nanoparticles promote drug accumulation at tumor sites, providing an effective strategy for an intelligent, responsive drug-delivery system. Tweetable abstractThis study prepared polymer nanocarriers (PLGA-b-p-NPs) with double response to the tumor microenvironment and loaded with traditional antitumor drug paclitaxel, so that drugs can accurately reach tumor cells and be rapidly released in cells. Plain language summaryCancer is one of the diseases with the highest mortality rate in the world. Chemotherapy is the most frequently used method of cancer treatment. However, traditional chemotherapeutic drugs have the disadvantages of lack of specificity, high toxicity to the human body, lack of tumor targeting, inability to exist stably in the body, ease of clearance by the body and drug resistance to tumors, so clinical application is limited. Paclitaxel is widely used in the treatment of various cancers, and its use is limited due to the above disadvantages. The purpose of this study was to construct a nanodelivery system with dual responses to the tumor microenvironment, enabling the efficient accumulation of paclitaxel in solid tumors through the enhanced permeability and retention effect, enhancing the therapeutic effect of cancer. This study also investigated the intravenous safety of this dual-responsive nanodelivery system. It evaluated the toxic effects of drug-loaded nanoparticles on cancer cells and validated the controlled release of nanoparticles at tumor sites by in vivo imaging in mice. The authors concluded that tumor microenvironment dual-responsive nanoparticles are a novel and promising nanodelivery system as an intelligently responsive anticancer agent with great promise in future clinical trials.

Redox- and MMP-2-sensitive Drug Delivery Nanoparticles Based on Gelatin and Albumin for Tumor Targeted Delivery of Paclitaxel.

Matrix Metalloproteinase-Sensitive Size-Shrinkable Nanoparticles for Deep Tumor Penetration and Ph Triggered Doxorubicin Release.

Zein-Paclitaxel Prodrug Nanoparticles for Redox-Triggered Drug Delivery and Enhanced Therapeutic Efficiency.

Redox-responsive paclitaxel-pentadecanoic acid conjugate encapsulated human serum albumin nanoparticles for cancer therapy

Enzymatic PEG-Poly(amine-co-disulfide ester) Nanoparticles as pH- and Redox-Responsive Drug Nanocarriers for Efficient Antitumor Treatment

Α-Amylase- and Redox-Responsive Nanoparticles for Tumor-Targeted Drug Delivery.

Fabrication of a pH/Redox-Triggered Mesoporous Silica-Based Nanoparticle with Microfluidics for Anticancer Drugs Doxorubicin and Paclitaxel Codelivery

Dual-Responsive Core-Crosslinked Polyphosphoester-Based Nanoparticles for Ph/Redox-Triggered Anticancer Drug Delivery

Preparation and in Vitro Properties of Redox-Responsive Polymeric Nanoparticles for Paclitaxel Delivery.

Poly(cystine-PCL) based pH/redox dual-responsive nanocarriers for enhanced tumor therapy.

Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.

Intelligently Targeted Drug Delivery and Enhanced Antitumor Effect by Gelatinase-Responsive Nanoparticles

Preparation and evaluation of paclitaxel-loaded reactive oxygen species and glutathione redox-responsive poly(lactic-co-glycolic acid) nanoparticles for controlled release in tumor cells

Redox-responsive Nanoparticles Based on Chondroitin Sulfate and Docetaxel Prodrug for Tumor Targeted Delivery of Docetaxel.

Redox-sensitive hyaluronic acid–paclitaxel conjugate micelles with high physical drug loading for efficient tumor therapy

Redox-sensitive Self-Assembled Nanoparticles Based on Alpha-Tocopherol Succinate-Modified Heparin for Intracellular Delivery of Paclitaxel.

Albumin-bound paclitaxel dimeric prodrug nanoparticles with tumor redox heterogeneity-triggered drug release for synergistic photothermal/chemotherapy

Ph and Redox Dual Responsive Carrier-Free Anticancer Drug Nanoparticles for Targeted Delivery and Synergistic Therapy

Zwitterionic Nanoparticles Constructed with Well-Defined Reduction-Responsive Shell and Ph-Sensitive Core for “spatiotemporally Pinpointed” Drug Delivery

Integrated Metalloproteinase, Ph and Glutathione Responsive Prodrug-Based Nanomedicine for Efficient Target Chemotherapy.

Fabrication of redox-responsive doxorubicin and paclitaxel prodrug nanoparticles with microfluidics for selective cancer therapy